Compare Smith & Nephew plc (SNN) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Under Armour Inc Class A — how do they compare? Smith & Nephew plc trades at $27.07 (market cap $11.10B), while Under Armour Inc Class A trades at $4.78 (market cap $2.07B). The key difference: Smith & Nephew plc is far larger — about 5.4× Under Armour Inc Class A's market cap, and Smith & Nephew plc pays a 2.95% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and Under Armour Inc Class A for 18 Days on average.
| SNN | UA | |
|---|---|---|
Market Cap | $11.10B | $2.07B |
Volume | 1,051,703 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $37.17 | $7.88 |
52-Week Low | $26.42 | $3.96 |
Typical Hold Time | 120 Days | 18 Days |
Enterprise Value | $14.13B | $3.05B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Under Armour (UA) trades at $4.75, up 1.06% with a bullish technical signal despite mixed earnings. The company reported Q2 2026 EPS beat but faces revenue declines and negative profitability metrics, including a -9.99% net income margin. Cash flow remains negative at -$362M for 2025, while analyst consensus shows 40% buy ratings amid ongoing operational challenges.
Outlook remains cautious with revenue guidance cuts and competitive pressures. Investment opportunity exists if turnaround strategies succeed, but risks include sustained negative cash flow, weak consumer demand, and high debt levels. The stock's low P/S ratio of 0.41 offers value potential if management can stabilize operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
